Targeted Protein Degradation– tag –
-
Nature Chemical Biology Reports Discovery of Novel E3 Ligase Modulators Opening Path to Intractable Protein Degradation
Nature Chemical Biology USA Overview A new study in Nature Chemical Biology identified novel E3 ligase modulators that can extend the scope of targeted protein degradation (TPD) to a new class of disease-related proteins. This discovery ... -
Kymera Therapeutics Initiates Phase 1 Clinical Trial for Oral STAT3 Degrader KT-XXX
Kymera Therapeutics Press Release USA Overview Kymera Therapeutics has announced the initiation of a Phase 1 clinical trial for its lead STAT3 degrader candidate, KT-XXX. The study aims to evaluate the safety, pharmacokinetics (PK), and ... -
Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation
Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA Overview Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseas...
